Publications by authors named "E Bertaglia"
Prescriptive Appropriateness and Efficacy of Cholesterol-Lowering Drugs in a Secondary Prevention Setting-A Retrospective Analysis from Two Italian Cardiac Rehabilitation Centers.
J Clin Med
December 2024
Treatment of CV risk factors, such as cholesterol level, represents one of the main goals to reduce atherosclerotic burden. The aim of this study was to investigate the prescriptive appropriateness of cholesterol-lowering drugs among patients who experienced an atherosclerotic CV disease (ASCVD). : We investigated 155 patients who underwent cardiac rehabilitation in 2020.
View Article and Find Full Text PDFBackground And Aims: The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.
Methods: These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease.
Background: Short and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device-detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness and safety of oral anticoagulation in patients with prior stroke or TIA and device-detected AF but with no ECG-documented AF is unclear.
Methods And Results: This prespecified analysis of the NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) trial with post hoc elements assessed the effect of oral anticoagulation in patients with device-detected AF with and without a prior stroke or TIA in the randomized, double-blind, double-dummy NOAH-AFNET 6 trial.
Article Synopsis
- Subclinical atrial fibrillation (AF) increases risks of developing clinical AF, stroke, and cardiovascular death; researchers aimed to test if closed loop stimulation (CLS) could reduce atrial high-rate episodes (AHREs) in pacemaker patients compared to conventional dual-chamber rate-adaptive pacing (DDDR).
- A study with 1,210 patients showed that those using CLS had a lower incidence of the primary endpoint (first AHRE lasting ≥6 min, stroke, or TIA) compared to DDDR over a 3-year period, particularly effective in patients without atrioventricular block or AF history.
- The findings suggest that dual-chamber CLS significantly reduces AHRE occurrence, highlighting its potential benefits for patients